DREAMS Evaluation


On World AIDS Day 2014, PEPFAR launched a bold new initiative – ‘DREAMS’ – to reduce new HIV infections by 40 percent among the highest risk adolescent girls and young women in 10 high-burden countries. With an initial commitment of US$385 million, quickly supplemented with $85 million for a DREAMS Innovation Fund, DREAMS partners – PEPFAR, Bill & Melinda Gates Foundation, Girl Effect, Johnson & Johnson, ViiV Healthcare and Gilead Sciences – aim to promote empowerment and prevent HIV acquisition through a core package of interventions for young women, their families, communities and male partners.

The Bill & Melinda Gates Foundation has awarded LSHTM a 4-year grant to lead a portfolio of evaluation studies designed to track the impact of DREAMS in Kenya, South Africa and Zimbabwe. Led by Isolde Birdthistle (EPH/DPH) and Sian Floyd (EPH/IDE), the evaluation draws on LSHTM expertise in HIV, adolescent health and evaluation across all faculties, and close research partnerships with experienced institutes in each country: the Africa Health Research Institute (AHRI), KwaZulu Natal, South Africa; the African Population and Health Research Centre (APHRC) in Nairobi; and Kenya Medical Research Institute (KEMRI) in Siaya, Kenya; and the Centre for Sexual Health HIV and AIDS Research (CeSHHAR) in Zimbabwe.

Comments are closed.